PIK3CB and neoplasm: Activation of PI3K in tumor cells leads to increased expression of PD-L1, which binds to CD8+ T cells and inhibits their activation through immune checkpoint mechanisms, thereby dampening the immune response and promoting tumor cell survival [20].